LAVAL, QC / ACCESS Newswire / December 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") and its subsidiary 1261229 B.C. Ltd. (the "Issuer" and, together with the Company, ...
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 23, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential ...
Samsung Biologics has agreed to acquire GlaxoSmithKline’s Human Genome Sciences and its two pharmaceutical manufacturing ...
Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney TransplantationThe application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly ...
Ondine and Mid Yorkshire Teaching NHS Trust shortlisted for Excellence in Healthcare Partnership Award for Reducing Surgical Site Infections with Nasal Photodisinfection Second national award ...
IFAD and the GEF announce three climate-resilience investments in rural people in Eritrea, Kiribati and MalawiRome, 22 December 2025. The International Fund for Agricultural Development (IFAD), in ...
Global Absorbable Sutures Market OverviewThe global absorbable sutures market is projected to grow at a steady rate of around 5% over the next five years, supported by the increasing number of ...
The global Orthobiologics Market, valued at $5.4 billion in 2021, is expected to grow at a rate of 7% annually through 2026. This growth is driven by factors such as an increasing number of sports ...
OverviewThe global NLP in healthcare & life sciences market is anticipated to expand at a CAGR of nearly 25% during the forecast period, fueled by widespread EHR adoption, rising interest in ...
Incentive scheme for rare disease drug development vital for sector, says leading biotechSynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly disease, says the ...
The United States accounts for a significant share of the global remote patient monitoring (RPM) market. The U.S. RPM market ...
Expedited Development Enabled by RMAT and Breakthrough Therapy StatusClinical Trial Initiation in 2026, FDA Approval Target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback